Mark Jacobson, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
AddressRemote Location
Varies 00001
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoM.D.1981 Medicine
    Kaiser Foundation Hospital, Oakland, CAInternship/Residency1984Medicine
    University of California, Los AngelesFellowship1986Infectious Diseases
    Collapse Awards and Honors
    UCSF2007Positive Health Program Teaching Award
    UCSF2013AIDS Research Institute Sarlo Award for Teaching Excellence

    Collapse Overview 
    Collapse Overview
    Dr. Jacobson is a clinician, educator, and researcher who specialized in HIV/AIDS and its complications after joining the UCSF faculty in 1986. His career began with leading multicenter, interventional trials that focused on developing effective treatments for AIDS-associated opportunistic infections. His subsequent research was translational, investigating protective immunity against chronic viral infections, in particular cytomegalovirus (CMV), HIV, and human papillomavirus (HPV). He taught medicine residents and medical students and provided clinical care in the Ward 86 HIV clinic at San Francisco General Hospital until March, 2020, when he moved to the Occupational Medicine division to become the infectious diseases consultant for a team of MDs, NPs and RNs who created a system to manage employee COVID-19 health issues for health care personnel working at SF General and affiliated SF Department of Public Health facilities. This included a Occupational Health Service COVID-19 Hotline and Hotline staff standard work guidance for testing/off-return to work decisions, vaccination, and management of COVID-19 vaccine adverse events. Dr. Jacobson initiated a quality improvement program that analyzes data collected by the Hotline to address questions regarding optimal employee management policies. His QI efforts have resulted in 4 medical journal publications to date. He continues to teach Hotline staff and Occupational Medicine residents, consult with Occupational Medicine leadership re policy changes and special issues that arise, and mentor junior faculty conducting observational studies of COVID-19 in health care personnel. Dr. Jacobson is also the author of Sensing Light, a novel published in 2016 about the unfolding of the AIDS epidemic in 1980s San Francisco from the perspective of front-line, treating physicians (see http://markajacobsonauthor.com/).
    Collapse Websites
    Collapse Mentoring

    Collapse Research 
    Collapse Research Activities and Funding
    Aberrant T Cell Function and Immunopathogenesis of CMV Immune Recovery Uveitis
    NIH R21EY018559Sep 1, 2007 - Aug 31, 2010
    Role: Principal Investigator
    HIV Epitope Specific T Cell Responses and Control of HIV Replication
    NIH R21AI068549May 15, 2007 - Apr 30, 2010
    Role: Principal Investigator
    CMV Immune Response &Long-Term Outcome of CMV Retinitis
    NIH R01EY015651Feb 1, 2004 - Jan 31, 2007
    Role: Principal Investigator
    Adjunct rhIL-12 enhance THI response to viral vaccine?
    NIH R01AI049538May 1, 2002 - Oct 31, 2005
    Role: Principal Investigator
    UCSF-Gladstone Center for AIDS Research
    NIH P30AI027763Sep 30, 1988 - Aug 31, 2022
    Role: Co-Investigator
    UCSF-GIVI CENTER FOR AIDS RESEARCH
    NIH P30MH059037Sep 30, 1988 - Feb 28, 2003
    Role: Co-Principal Investigator
    ADULT AIDS CLINICAL TRIALS UNIT
    NIH U01AI027663Jun 30, 1986 - Dec 31, 2006
    Role: Co-Principal Investigator
    General Clinical Research Center
    NIH M01RR000083Oct 1, 1974 - Nov 30, 2007
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Risk of subsequent SARS-CoV-2 infection among vaccinated employees with or without hybrid immunity acquired early in the Omicron-predominant era of the COVID-19 pandemic. Am J Ind Med. 2024 Apr; 67(4):334-340. Jacobson MA, Blanc PD, Tulsky J, Tilly M, Meister R, Huen W, McNicholas JE. PMID: 38316635.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsPHPublic Health
    2. A Rapid Nucleic Acid Amplification Test-Based, Conditional Release-to-Work Policy for Health Care Personnel With Symptoms Consistent With COVID-19. J Occup Environ Med. 2023 02 01; 65(2):125-127. Jacobson MA, Hart C, Huen W, Suarez Guardado G, Villanueva A, Whitman J, Blanc PD. PMID: 36240750; PMCID: PMC9897112.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    3. Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine (Moderna) in a Cohort of Hospital Employees. Clin Infect Dis. 2022 03 01; 74(4):591-596. Jacobson MA, Zakaria A, Maung Z, Hart C, McCalmont TH, Fassett M, Amerson E. PMID: 34086881; PMCID: PMC8244618.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    4. Temperature Screening of Healthcare Personnel Is Ineffective in Controlling COVID-19. J Occup Environ Med. 2022 05 01; 64(5):382-384. Maung Z, Kristensen M, Hoffman B, Jacobson MA. PMID: 35166255.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsPHPublic Health
    5. Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status. AIDS. 2018 06 19; 32(10):1279-1287. Presti RM, Handley SA, Droit L, Ghannoum M, Jacobson M, Shiboski CH, Webster-Cyriaque J, Brown T, Yin MT, Overton ET. PMID: 29851662; PMCID: PMC6198320.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    6. Human papillomavirus infection in the oral cavity of HIV patients is not reduced by initiating antiretroviral therapy. AIDS. 2016 06 19; 30(10):1573-82. Shiboski CH, Lee A, Chen H, Webster-Cyriaque J, Seaman T, Landovitz RJ, John M, Reilly N, Naini L, Palefsky J, Jacobson MA. PMID: 26919735; PMCID: PMC4900420.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    7. Regulatory T cells and the risk of CMV end-organ disease in patients with AIDS. J Acquir Immune Defic Syndr. 2014 May 01; 66(1):25-32. Weinberg A, Bosch R, Bennett K, Tovar-Salazar A, Benson CA, Collier AC, Zolopa A, Gulick RM, Wohl D, Polsky B, Erice A, Jacobson MA. PMID: 24378728; PMCID: PMC3981937.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    8. The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit. PLoS One. 2013; 8(11):e78676. Wohl DA, Kendall MA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Benson C, Keiser P, van der Horst C, Jacobson MA, A5030 Study Team. PMID: 24260125; PMCID: PMC3829816.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsCTClinical Trials
    9. Asymptomatic cryptococcemia in resource-limited settings. Curr HIV/AIDS Rep. 2013 Sep; 10(3):254-63. Meyer AC, Jacobson M. PMID: 23715897; PMCID: PMC3809900.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    10. Cytomegalovirus viraemia in the modern antiretroviral era(*). HIV Med. 2011 Aug; 12(7):387-8. Jacobson M, Lurain N, Hunt P. PMID: 21729228.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    11. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis. 2011 May 15; 203(10):1474-83. Hunt PW, Martin JN, Sinclair E, Epling L, Teague J, Jacobson MA, Tracy RP, Corey L, Deeks SG. PMID: 21502083; PMCID: PMC3080892.
      View in: PubMed   Mentions: 190     Fields:    Translation:HumansCells
    12. Development of cytomegalovirus (CMV) immune recovery uveitis is associated with Th17 cell depletion and poor systemic CMV-specific T cell responses. Clin Infect Dis. 2011 Feb 01; 52(3):409-17. Hartigan-O'Connor DJ, Jacobson MA, Tan QX, Sinclair E, Studies of Ocular Complications of AIDS Research Group. PMID: 21189271; PMCID: PMC3060886.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    13. Life-threatening immune reconstitution inflammatory syndrome after Pneumocystis pneumonia: a cautionary case series. AIDS. 2009 Aug 24; 23(13):1794-6. Jagannathan P, Davis E, Jacobson M, Huang L. PMID: 19684486.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    14. Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030. HIV Clin Trials. 2009 May-Jun; 10(3):143-52. Wohl DA, Kendall MA, Andersen J, Crumpacker C, Spector SA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Lurain N, Jabs D, Benson C, Keiser P, Jacobson MA, A5030 Study Team. PMID: 19632953; PMCID: PMC2754189.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    15. Human herpesvirus replication and abnormal CD8+ T cell activation and low CD4+ T cell counts in antiretroviral-suppressed HIV-infected patients. PLoS One. 2009; 4(4):e5277. Jacobson MA, Ditmer DP, Sinclair E, Martin JN, Deeks SG, Hunt P, Mocarski ES, Shiboski C. PMID: 19381272; PMCID: PMC2667217.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    16. A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain). Vaccine. 2009 Mar 04; 27(10):1540-8. Jacobson MA, Adler SP, Sinclair E, Black D, Smith A, Chu A, Moss RB, Wloch MK. PMID: 19168107.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    17. Recurrence of skin and soft tissue infection caused by methicillin-resistant Staphylococcus aureus in a HIV primary care clinic. J Acquir Immune Defic Syndr. 2008 Oct 01; 49(2):231-3. Graber CJ, Jacobson MA, Perdreau-Remington F, Chambers HF, Diep BA. PMID: 18820536.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    18. Poor predictive value of cytomegalovirus (CMV)-specific T cell assays for the development of CMV retinitis in patients with AIDS. Clin Infect Dis. 2008 Feb 01; 46(3):458-66. Jacobson MA, Tan QX, Girling V, Poon C, Van Natta M, Jabs DA, Inokuma M, Maecker HT, Bredt B, Sinclair E, Studies of Ocular Complications of AIDS Research Group. PMID: 18173357; PMCID: PMC2666016.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    19. Do CD4+ T cell functional responses to Epstein-Barr virus provide protective immunity against CNS lymphoma in AIDS? PLoS Med. 2007 Mar 27; 4(3):e110. Jacobson MA. PMID: 17388670; PMCID: PMC1831741.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    20. Protective immunity to cytomegalovirus (CMV) retinitis in AIDS is associated with CMV-specific T cells that express interferon- gamma and interleukin-2 and have a CD8+ cell early maturational phenotype. J Infect Dis. 2006 Dec 01; 194(11):1537-46. Sinclair E, Tan QX, Sharp M, Girling V, Poon C, Natta MV, Jabs DA, Inokuma M, Maecker HT, Bredt B, Jacobson MA, Studies of Ocular Complications of AIDS Research Group. PMID: 17083038.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    21. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12. Vaccine. 2006 Jun 19; 24(25):5311-9. Jacobson MA, Sinclair E, Bredt B, Agrillo L, Black D, Epling CL, Carvidi A, Ho T, Bains R, Girling V, Adler SP. PMID: 16701925.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCellsCTClinical Trials
    22. Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients. J Clin Virol. 2006 Mar; 35(3):332-7. Jacobson MA, Sinclair E, Bredt B, Agrillo L, Black D, Epling CL, Carvidi A, Ho T, Bains R, Adler SP. PMID: 16387547.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    23. Pharmacokinetics of clarithromycin extended-release (ER) tablets in patients with AIDS. HIV Clin Trials. 2005 Sep-Oct; 6(5):246-53. Jacobson MA, Nicolau DP, Sutherland C, Smith A, Aweeka F. PMID: 16306031.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    24. The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy. HIV Clin Trials. 2005 May-Jun; 6(3):136-46. Wohl DA, Kendall MA, Owens S, Holland G, Nokta M, Spector SA, Schrier R, Fiscus S, Davis M, Jacobson MA, Currier JS, Squires K, Alston-Smith B, Andersen J, Freeman WR, Higgins M, Torriani FJ, ACTG 379 Study Team. PMID: 16192248.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCellsCTClinical Trials
    25. Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology. 2005 May; 112(5):771-9. Jabs DA, Holbrook JT, Van Natta ML, Clark R, Jacobson MA, Kempen JH, Murphy RL, Studies of Ocular Complications of AIDS Research Group. PMID: 15878056.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    26. Editorial comment: failure of HAART to reconstitute CMV-specific protective immunity. AIDS Read. 2005 Apr; 15(4):188. Jacobson MA. PMID: 15844239.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    27. Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067. J Clin Immunol. 2005 Mar; 25(2):106-15. D'Amico R, Yang Y, Mildvan D, Evans SR, Schnizlein-Bick CT, Hafner R, Webb N, Basar M, Zackin R, Jacobson MA. PMID: 15821887.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCellsCTClinical Trials
    28. The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283). Clin Pharmacol Ther. 2004 Oct; 76(4):313-22. Winter HR, Trapnell CB, Slattery JT, Jacobson M, Greenspan DL, Hooton TM, Unadkat JD. PMID: 15470330.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsCTClinical Trials
    29. Abundant expression of granzyme A, but not perforin, in granules of CD8+ T cells in GALT: implications for immune control of HIV-1 infection. J Immunol. 2004 Jul 01; 173(1):641-8. Shacklett BL, Cox CA, Quigley MF, Kreis C, Stollman NH, Jacobson MA, Andersson J, Sandberg JK, Nixon DF. PMID: 15210827.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    30. Results of a cytomegalovirus (CMV)-specific CD8+/interferon- gamma+ cytokine flow cytometry assay correlate with clinical evidence of protective immunity in patients with AIDS with CMV retinitis. J Infect Dis. 2004 Apr 15; 189(8):1362-73. Jacobson MA, Maecker HT, Orr PL, D'Amico R, Van Natta M, Li XD, Pollard RB, Bredt BM, Adult AIDS Clinical Trials Group and the Studies of Ocular Complications of AIDS Research Group. PMID: 15073672.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    31. Avidity of antibodies to cytomegalovirus in HIV-seropositive patients with and without CMV retinitis. Viral Immunol. 2004; 17(1):101-8. Marshall BC, Jacobson MA, Adler SP, Studies Of Ocular Complications Of AIDS Research Group. PMID: 15018666.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    32. CMV antigen-specific CD4+ and CD8+ T cell IFNgamma expression and proliferation responses in healthy CMV-seropositive individuals. Viral Immunol. 2004; 17(3):445-54. Sinclair E, Black D, Epling CL, Carvidi A, Josefowicz SZ, Bredt BM, Jacobson MA. PMID: 15357911; PMCID: PMC1993826.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    33. Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection. J Infect Dis. 2003 Dec 15; 188(12):1804-14. Jacobson JM, Lederman MM, Spritzler J, Valdez H, Tebas P, Skowron G, Wang R, Jackson JB, Fox L, Landay A, Gilbert MJ, O'Neil D, Bancroft L, Al-Harthi L, Jacobson MA, Merigan TC, Glesby MJ, National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. PMID: 14673758.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsCTClinical Trials
    34. Trafficking of human immunodeficiency virus type 1-specific CD8+ T cells to gut-associated lymphoid tissue during chronic infection. J Virol. 2003 May; 77(10):5621-31. Shacklett BL, Cox CA, Sandberg JK, Stollman NH, Jacobson MA, Nixon DF. PMID: 12719554; PMCID: PMC154016.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    35. Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapy. AIDS. 2003 Apr 11; 17(6):917-9. Jacobson MA, Liu L, Khayam-Bashi H, Deeks SG, Hecht FM, Kahn J. PMID: 12660541.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    36. Effect of long-term highly active antiretroviral therapy in restoring HIV-induced abnormal B-lymphocyte function. J Acquir Immune Defic Syndr. 2002 Dec 15; 31(5):472-7. Jacobson MA, Khayam-Bashi H, Martin JN, Black D, Ng V. PMID: 12473834.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCellsCTClinical Trials
    37. Cytomegalovirus (CMV) polymerase chain reaction profiles in individuals with advanced human immunodeficiency virus infection: relationship to CMV disease. J Infect Dis. 2002 Jun 15; 185(12):1717-22. Nokta MA, Holland F, De Gruttola V, Emery VC, Jacobson MA, Griffiths P, Pollard RB, Feinberg JE, AIDS Clinical Trials Group, Protocol 204/GlaxoWellcome 123-014, International CMV Prophylaxis Study . PMID: 12085316.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsCTClinical Trials
    38. A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection. AIDS. 2002 May 24; 16(8):1147-54. Jacobson MA, Spritzler J, Landay A, Chan E, Katzenstein D, Schock B, Fox L, Roe J, Kundu S, Pollard R, AACTG 325 Protocol Team. PMID: 12004273.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCellsCTClinical Trials
    39. Presence of macrolide resistance in respiratory flora of HIV-Infected patients receiving either clarithromycin or azithromycin for Mycobacterium avium complex prophylaxis. HIV Clin Trials. 2001 Nov-Dec; 2(6):453-9. Aberg JA, Wong MK, Flamm R, Notario GF, Jacobson MA. PMID: 11742432.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    40. Cytomegalovirus (CMV)-specific CD4+ T lymphocyte immune function in long-term survivors of AIDS-related CMV end-organ disease who are receiving potent antiretroviral therapy. J Infect Dis. 2001 May 01; 183(9):1399-404. Jacobson MA, Schrier R, McCune JM, Torriani FJ, Holland GN, O'Donnell JJ, Freeman WR, Bredt BM. PMID: 11294673.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    41. Invasive fungal sinusitis and meningitis due to Arthrographis kalrae in a patient with AIDS. J Clin Microbiol. 2001 Feb; 39(2):804-7. Chin-Hong PV, Sutton DA, Roemer M, Jacobson MA, Aberg JA. PMID: 11158158; PMCID: PMC87827.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    42. A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 in HIV-infected subjects. AIDS. 2000 Nov 10; 14(16):2503-8. Angel JB, Jacobson MA, Skolnik PR, Giordano M, Shapiro L, LeBeaut A, Greaves W, Fuchs AC. PMID: 11101061.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    43. Phase 1 trial of a single dose of recombinant human interleukin-12 in human immunodeficiency virus-infected patients with 100-500 CD4 cells/microL. J Infect Dis. 2000 Oct; 182(4):1070-6. Jacobson MA, Hardy D, Connick E, Watson J, DeBruin M. PMID: 10979901.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    44. Natural history and outcome of new AIDS-related cytomegalovirus retinitis diagnosed in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000 Jan; 30(1):231-3. Jacobson MA, Stanley H, Holtzer C, Margolis TP, Cunningham ET. PMID: 10619774.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    45. Effect of renal disease and hemodialysis on foscarnet pharmacokinetics and dosing recommendations. J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Apr 01; 20(4):350-7. Aweeka FT, Jacobson MA, Martin-Munley S, Hedman A, Schoenfeld P, Omachi R, Tsunoda S, Gambertoglio JG. PMID: 10096579.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    46. Editorial comment: when to discontinue maintenance therapy for OIs in patients on HAART. AIDS Read. 1999 Mar-Apr; 9(2):124. Jacobson MA. PMID: 12728895.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    47. Phase I study of combination therapy with intravenous cidofovir and oral ganciclovir for cytomegalovirus retinitis in patients with AIDS. Clin Infect Dis. 1999 Mar; 28(3):528-33. Jacobson MA, Wilson S, Stanley H, Holtzer C, Cherrington J, Safrin S. PMID: 10194072.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    48. Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Jan 01; 20(1):34-8. Robles R, Lugo D, Gee L, Jacobson MA. PMID: 9928727.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    49. Eradication of AIDS-related disseminated mycobacterium avium complex infection after 12 months of antimycobacterial therapy combined with highly active antiretroviral therapy. J Infect Dis. 1998 Nov; 178(5):1446-9. Aberg JA, Yajko DM, Jacobson MA. PMID: 9780266.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsCTClinical Trials
    50. Absence of effect of glutamic acid hydrochloride on the bioavailability of oral ganciclovir in AIDS patients with cytomegalovirus disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Aug 01; 18(4):394-6. Gambertoglio J, Kumar P, Dieterich D, Jacobson MA. PMID: 9704949.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    51. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med. 1998 Aug; 4(8):953-6. Komanduri KV, Viswanathan MN, Wieder ED, Schmidt DK, Bredt BM, Jacobson MA, McCune JM. PMID: 9701250.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansCells
    52. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA. Arch Intern Med. 1998 May 11; 158(9):957-69. Whitley RJ, Jacobson MA, Friedberg DN, Holland GN, Jabs DA, Dieterich DT, Hardy WD, Polis MA, Deutsch TA, Feinberg J, Spector SA, Walmsley S, Drew WL, Powderly WG, Griffiths PD, Benson CA, Kessler HA. PMID: 9588429.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    53. AIDS-related cytomegalovirus retinitis. Drugs Today (Barc). 1998 May; 34(5):409-13. Jacobson MA. PMID: 15010704.
      View in: PubMed   Mentions: 5     Fields:    
    54. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol. 1998 Mar; 125(3):292-300. Zegans ME, Walton RC, Holland GN, O'Donnell JJ, Jacobson MA, Margolis TP. PMID: 9512145.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    55. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. J Infect Dis. 1998 Jan; 177(1):48-56. Feinberg JE, Hurwitz S, Cooper D, Sattler FR, MacGregor RR, Powderly W, Holland GN, Griffiths PD, Pollard RB, Youle M, Gill MJ, Holland FJ, Power ME, Owens S, Coakley D, Fry J, Jacobson MA. PMID: 9419169.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    56. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group. AIDS. 1998 Jan 01; 12(1):65-74. Kuritzkes DR, Parenti D, Ward DJ, Rachlis A, Wong RJ, Mallon KP, Rich WJ, Jacobson MA. PMID: 9456256.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCellsCTClinical Trials
    57. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy. AIDS. 1998; 12 Suppl A:S157-63. Jacobson MA, French M. PMID: 9632998.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    58. Ganciclovir therapy for severe cytomegalovirus infection in immunocompetent patients. Clin Infect Dis. 1997 Dec; 25(6):1487-8. Jacobson MA. PMID: 9431412.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    59. AIDS-related disseminated histoplasmosis in San Francisco, California. West J Med. 1997 Nov; 167(5):315-21. Fredricks DN, Rojanasthien N, Jacobson MA. PMID: 9392979; PMCID: PMC1304617.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    60. Human immunodeficiency virus disease-related neutropenia and the risk of hospitalization for bacterial infection. Arch Intern Med. 1997 Sep 08; 157(16):1825-31. Jacobson MA, Liu RC, Davies D, Cohen PT. PMID: 9290541.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    61. Severe reversible thrombocytopenia caused by recombinant human granulocyte colony-stimulating factor in an AIDS patient receiving chronic ganciclovir therapy. AIDS. 1997 Sep; 11(11):1403-5. Holtzer CD, Stanley HD, Jacobson MA. PMID: 9302457.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    62. Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1997 Jul 10; 337(2):105-14. Jacobson MA. PMID: 9211681.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    63. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet. 1997 May 17; 349(9063):1443-5. Jacobson MA, Zegans M, Pavan PR, O'Donnell JJ, Sattler F, Rao N, Owens S, Pollard R. PMID: 9164318.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    64. Re-evaluation of time to progression of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients clinically resistant to ganciclovir. AIDS. 1997 Mar; 11(3):397-9. Mueller AJ, Jacobson MA, Hurwitz S, Chuang EL, Friedberg DN, Haidt SJ, Heinemann MH, Jabs DA, Kaplan HJ, Freeman WR. PMID: 9147441.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    65. Interleukin-12 administered in vivo decreases human NK cell cytotoxicity and antibody-dependent cellular cytotoxicity to human immunodeficiency virus-infected cells. J Infect Dis. 1996 Nov; 174(5):1105-8. Kohl S, Sigaroudinia M, Charlebois ED, Jacobson MA. PMID: 8896517.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    66. Diagnosis of neurosyphilis in patients infected with human immunodeficiency virus type 1. J Infect Dis. 1996 Jul; 174(1):219-21. Marra CM, Gary DW, Kuypers J, Jacobson MA. PMID: 8655999.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    67. Population pharmacokinetics of didanosine in patients with human immunodeficiency virus infection. J Infect Dis. 1996 Jan; 173(1):273. Harb GE, Mandema JW, Delahunty T, Benowitz NB, Coleman R, Sheiner LB, Jacobson MA. PMID: 8537676.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    68. Zidovudine side effects as reported by black, Hispanic, and white/non-Hispanic patients with early HIV disease: combined analysis of two multicenter placebo-controlled trials. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jan 01; 11(1):45-52. Jacobson MA, Gundacker H, Hughes M, Fischl M, Volberding P. PMID: 8528732.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsCTClinical Trials
    69. Current management of cytomegalovirus retinitis in AIDS update on ganciclovir and foscarnet for CMV infections. Adv Exp Med Biol. 1996; 394:85-92. Jacobson MA. PMID: 8815712.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    70. The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine. AIDS. 1995 Jul; 9(7):727-34. Jacobson MA, De Gruttola V, Reddy M, Arduino JM, Strickland S, Reichman RC, Bartlett JA, Phair JP, Hirsch MS, Collier AC, et al. PMID: 7546418.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    71. Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group. J Infect Dis. 1995 Jun; 171(6):1431-7. Spector SA, Busch DF, Follansbee S, Squires K, Lalezari JP, Jacobson MA, Connor JD, Jung D, Shadman A, Mastre B, et al. PMID: 7769276.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    72. Dose-related difference in progression rates of cytomegalovirus retinopathy during foscarnet maintenance therapy. AIDS Clinical Trials Group Protocol 915 Team. Am J Ophthalmol. 1995 May; 119(5):576-86. Holland GN, Levinson RD, Jacobson MA. PMID: 7733183.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    73. Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis. Clin Pharmacol Ther. 1995 Apr; 57(4):403-12. Aweeka FT, Gambertoglio JG, Kramer F, van der Horst C, Polsky B, Jayewardene A, Lizak P, Emrick L, Tong W, Jacobson MA. PMID: 7712668.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    74. Update (1995) on clinical trials of antiviral therapy and prophylaxis for AIDS-related cytomegalovirus disease. Scand J Infect Dis Suppl. 1995; 99:96-9. Jacobson MA. PMID: 8668951.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    75. Relationship between plasma concentrations of 3'-deoxy-3'-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials. J Infect Dis. 1994 Dec; 170(6):1394-403. Flexner C, van der Horst C, Jacobson MA, Powderly W, Duncanson F, Ganes D, Barditch-Crovo PA, Petty BG, Baron PA, Armstrong D, et al. PMID: 7995977.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCellsCTClinical Trials
    76. Microbiology of community-acquired bacterial pneumonia in persons with and at risk for human immunodeficiency virus type 1 infection. Implications for rational empiric antibiotic therapy. Arch Intern Med. 1994 Nov 28; 154(22):2589-96. Burack JH, Hahn JA, Saint-Maurice D, Jacobson MA. PMID: 7979856.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    77. Current management of cytomegalovirus disease in patients with AIDS. AIDS Res Hum Retroviruses. 1994 Aug; 10(8):917-23. Jacobson MA. PMID: 7811543.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    78. Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS clinical Trials Group Protocol 151. J Infect Dis. 1994 Jul; 170(1):189-93. Jacobson MA, Kramer F, Bassiakos Y, Hooton T, Polsky B, Geheb H, O'Donnell JJ, Walker JD, Korvick JA, van der Horst C. PMID: 8014496.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    79. Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother. 1994 Jul; 38(7):1534-40. Jacobson MA, Gallant J, Wang LH, Coakley D, Weller S, Gary D, Squires L, Smiley ML, Blum MR, Feinberg J. PMID: 7979285; PMCID: PMC284589.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    80. Pharmacodynamic relationship of pharmacokinetic parameters of maintenance doses of foscarnet and clinical outcome of cytomegalovirus retinitis. Antimicrob Agents Chemother. 1994 May; 38(5):1190-3. Jacobson MA, Polsky B, Causey D, Davis R, Tong W, O'Donnell JJ, Kuppermann BD, Heinemann MH, Feinberg J, Lizak P, et al. PMID: 8067763; PMCID: PMC188177.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    81. Phase II dose-ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG protocol 093). AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. AIDS. 1994 Apr; 8(4):451-9. Jacobson MA, Wulfsohn M, Feinberg JE, Davis R, Power M, Owens S, Causey D, Heath-Chiozzi ME, Murphy RL, Cheung TW, et al. PMID: 8011248.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    82. Central venous catheter infections in AIDS patients receiving treatment for cytomegalovirus disease. J Acquir Immune Defic Syndr (1988). 1994 Mar; 7(3):272-8. Stanley HD, Charlebois E, Harb G, Jacobson MA. PMID: 8106966.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    83. Mycobacterium avium complex in the respiratory or gastrointestinal tract and the risk of M. avium complex bacteremia in patients with human immunodeficiency virus infection. J Infect Dis. 1994 Feb; 169(2):289-95. Chin DP, Hopewell PC, Yajko DM, Vittinghoff E, Horsburgh CR, Hadley WK, Stone EN, Nassos PS, Ostroff SM, Jacobson MA, et al. PMID: 7906290.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    84. Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced human immunodeficiency virus disease: results of a randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS. J Infect Dis. 1994 Feb; 169(2):384-94. Jacobson MA, Besch CL, Child C, Hafner R, Matts JP, Muth K, Wentworth DN, Neaton JD, Abrams D, Rimland D, et al. PMID: 8106772.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    85. A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. J Infect Dis. 1993 Aug; 168(2):444-8. Jacobson MA, Causey D, Polsky B, Hardy D, Chown M, Davis R, O'Donnell JJ, Kuppermann BD, Heinemann MH, Holland GN, et al. PMID: 8393058.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    86. Pharmacoepidemiology of adverse drug reactions in hospitalized patients with human immunodeficiency virus disease. J Acquir Immune Defic Syndr (1988). 1993 Aug; 6(8):919-26. Harb GE, Alldredge BK, Coleman R, Jacobson MA. PMID: 8315576.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    87. Randomized, placebo-controlled trial of rifampin, ethambutol, and ciprofloxacin for AIDS patients with disseminated Mycobacterium avium complex infection. J Infect Dis. 1993 Jul; 168(1):112-9. Jacobson MA, Yajko D, Northfelt D, Charlebois E, Gary D, Brosgart C, Sanders CA, Hadley WK. PMID: 8515098.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    88. Human immunodeficiency virus (HIV) infection. Does it increase susceptibility to adverse drug reactions? Drug Saf. 1993 Jul; 9(1):1-8. Harb GE, Jacobson MA. PMID: 8347288.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    89. An open-label dose-escalation trial of oral dehydroepiandrosterone tolerance and pharmacokinetics in patients with HIV disease. J Acquir Immune Defic Syndr (1988). 1993 May; 6(5):459-65. Dyner TS, Lang W, Geaga J, Golub A, Stites D, Winger E, Galmarini M, Masterson J, Jacobson MA. PMID: 8097787.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsCTClinical Trials
    90. Tolerability of combined ganciclovir and didanosine for the treatment of cytomegalovirus disease associated with AIDS. Clin Infect Dis. 1993 Feb; 16 Suppl 1:S69-73. Jacobson MA, Owen W, Campbell J, Brosgart C, Abrams DI. PMID: 8381032.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    91. Valaciclovir (BW256U87): the L-valyl ester of acyclovir. J Med Virol. 1993; Suppl 1:150-3. Jacobson MA. PMID: 8245883.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimals
    92. Drug hypersensitivity reactions and human immunodeficiency virus disease. J Acquir Immune Defic Syndr (1988). 1992 Dec; 5(12):1237-57. Bayard PJ, Berger TG, Jacobson MA. PMID: 1453334.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    93. Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis. J Infect Dis. 1992 Sep; 166(3):607-10. Reddy MM, Grieco MH, McKinley GF, Causey DM, van der Horst CM, Parenti DM, Hooton TM, Davis RB, Jacobson MA. PMID: 1323624.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    94. Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053). Antimicrob Agents Chemother. 1992 Aug; 36(8):1773-8. Aweeka FT, Gambertoglio JG, van der Horst C, Raasch R, Jacobson MA. PMID: 1416864; PMCID: PMC192046.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    95. Ganciclovir with recombinant methionyl human granulocyte colony-stimulating factor for treatment of cytomegalovirus disease in AIDS patients. AIDS. 1992 May; 6(5):515-7. Jacobson MA, Stanley HD, Heard SE. PMID: 1377475.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    96. Maintenance therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: foscarnet. Am J Med. 1992 Feb 14; 92(2A):26S-29S. Jacobson MA. PMID: 1310573.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    97. Toxicity of clindamycin as prophylaxis for AIDS-associated toxoplasmic encephalitis. Community Programs for Clinical Research on AIDS. Lancet. 1992 Feb 08; 339(8789):333-4. Jacobson MA, Besch CL, Child C, Hafner R, Matts JP, Muth K, Wentworth DN, Deyton L. PMID: 1346413.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCTClinical Trials
    98. Review of the toxicities of foscarnet. J Acquir Immune Defic Syndr (1988). 1992; 5 Suppl 1:S11-7. Jacobson MA. PMID: 1534839.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    99. Early predictors of survival in symptomatic HIV-infected persons treated with high-dose zidovudine. J Acquir Immune Defic Syndr (1988). 1992; 5(7):732-6. Bacchetti P, Moss AR, Andrews JC, Jacobson MA. PMID: 1535375.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    100. Natural history of disseminated Mycobacterium avium complex infection in AIDS. J Infect Dis. 1991 Nov; 164(5):994-8. Jacobson MA, Hopewell PC, Yajko DM, Hadley WK, Lazarus E, Mohanty PK, Modin GW, Feigal DW, Cusick PS, Sande MA. PMID: 1682396.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCells
    101. Decreased serum dehydroepiandrosterone is associated with an increased progression of human immunodeficiency virus infection in men with CD4 cell counts of 200-499. J Infect Dis. 1991 Nov; 164(5):864-8. Jacobson MA, Fusaro RE, Galmarini M, Lang W. PMID: 1682393.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    102. Survival of patients with AIDS and cytomegalovirus disease treated with ganciclovir or foscarnet. AIDS. 1991 Aug; 5(8):959-65. Harb GE, Bacchetti P, Jacobson MA. PMID: 1663770.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    103. Morbidity and mortality of patients with AIDS and first-episode Pneumocystis carinii pneumonia unaffected by concomitant pulmonary cytomegalovirus infection. Am Rev Respir Dis. 1991 Jul; 144(1):6-9. Jacobson MA, Mills J, Rush J, Peiperl L, Seru V, Mohanty PK, Hopewell PC, Hadley WK, Broadus VC, Leoung G, et al. PMID: 1648316.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    104. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. J Infect Dis. 1991 Jun; 163(6):1348-51. Jacobson MA, Drew WL, Feinberg J, O'Donnell JJ, Whitmore PV, Miner RD, Parenti D. PMID: 1645385.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    105. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. J Clin Endocrinol Metab. 1991 May; 72(5):1130-5. Jacobson MA, Gambertoglio JG, Aweeka FT, Causey DM, Portale AA. PMID: 1827127.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    106. Clinical programs for clinical research on AIDS: description of a randomized prospective study of clindamycin versus pyrimethamine for prevention of Toxoplasma gondii infection. Eur J Clin Microbiol Infect Dis. 1991 Mar; 10(3):195-8. Jacobson MA, Besch CL, Child C, Hafner R, Muth K, Deyton L. PMID: 1676364.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsCTClinical Trials
    107. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. BMJ. 1991 Jan 12; 302(6768):73-8. Jacobson MA, Bacchetti P, Kolokathis A, Chaisson RE, Szabo S, Polsky B, Valainis GT, Mildvan D, Abrams D, Wilber J, et al. PMID: 1671651; PMCID: PMC1668875.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    108. Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet. J Acquir Immune Defic Syndr (1988). 1991; 4 Suppl 1:S11-5. Jacobson MA, O'Donnell JJ. PMID: 1848616.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    109. Cytomegalovirus esophagitis in patients with AIDS. A clinical, endoscopic, and pathologic correlation. Ann Intern Med. 1990 Oct 15; 113(8):589-93. Wilcox CM, Diehl DL, Cello JP, Margaretten W, Jacobson MA. PMID: 2169217.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    110. Campylobacter-like organisms are uncommon pathogens in patients infected with the human immunodeficiency virus. J Clin Microbiol. 1990 Oct; 28(10):2370-1. Wilcox CM, Byford BA, Forsmark CE, Hadley WK, Cello JP, Jacobson MA. PMID: 2229366; PMCID: PMC268182.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    111. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial. N Engl J Med. 1990 Sep 20; 323(12):769-75. Leoung GS, Feigal DW, Montgomery AB, Corkery K, Wardlaw L, Adams M, Busch D, Gordon S, Jacobson MA, Volberding PA, et al. PMID: 1975426.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCellsCTClinical Trials
    112. Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis. Ann Intern Med. 1990 Jun 15; 112(12):955-6. Farese RV, Schambelan M, Hollander H, Stringari S, Jacobson MA. PMID: 2160217.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    113. Red cell transfusion therapy for anemia in patients with AIDS and ARC: incidence, associated factors, and outcome. Transfusion. 1990 Feb; 30(2):133-7. Jacobson MA, Peiperl L, Volberding PA, Porteous D, Toy PT, Feigal D. PMID: 2305441.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    114. Determination of phosphonoformic acid in human plasma and urine by high-performance liquid chromatography with electrochemical detection. J Chromatogr. 1990 Jan 26; 525(1):133-40. Hassanzadeh MK, Aweeka FT, Wu S, Jacobson MA, Gambertoglio JG. PMID: 2140113.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    115. Failure of adjunctive cytomegalovirus intravenous immune globulin to improve efficacy of ganciclovir in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: a phase 1 study. Antimicrob Agents Chemother. 1990 Jan; 34(1):176-8. Jacobson MA, O'Donnell JJ, Rousell R, Dionian B, Mills J. PMID: 2158273; PMCID: PMC171546.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    116. Serum beta 2-microglobulin decreases in patients with AIDS or ARC treated with azidothymidine. J Infect Dis. 1989 Jun; 159(6):1029-36. Jacobson MA, Abrams DI, Volberding PA, Bacchetti P, Wilber J, Chaisson RE, Crowe S, Howard W, Moss A. PMID: 2566637.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCellsCTClinical Trials
    117. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. Antimicrob Agents Chemother. 1989 May; 33(5):742-5. Aweeka F, Gambertoglio J, Mills J, Jacobson MA. PMID: 2546491; PMCID: PMC172525.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    118. Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial. Ann Intern Med. 1989 May 01; 110(9):710-3. Erlich KS, Jacobson MA, Koehler JE, Follansbee SE, Drennan DP, Gooze L, Safrin S, Mills J. PMID: 2522751.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    119. Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Antimicrob Agents Chemother. 1989 May; 33(5):736-41. Jacobson MA, O'Donnell JJ, Mills J. PMID: 2546490; PMCID: PMC172524.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    120. Cytomegalovirus infection of the laryngeal nerve presenting as hoarseness in patients with acquired immunodeficiency syndrome. Am J Med. 1989 Jan; 86(1):108-10. Small PM, McPhaul LW, Sooy CD, Wofsy CB, Jacobson MA. PMID: 2535917.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    121. Zidovudine-induced fever. J Acquir Immune Defic Syndr (1988). 1989; 2(4):382-8. Jacobson MA, McGrath MS, Joseph P, Molaghan JB, Tadepalli S, Quinn R. PMID: 2666640.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    122. Cotton-wool spots and cytomegalovirus retinitis in AIDS. Int Ophthalmol Clin. 1989; 29(2):105-7. O'Donnell JJ, Jacobson MA. PMID: 2541095.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    123. Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS. J Infect Dis. 1988 Oct; 158(4):862-5. Jacobson MA, Crowe S, Levy J, Aweeka F, Gambertoglio J, McManus N, Mills J. PMID: 2844921.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    124. Failure of antiviral therapy for acquired immunodeficiency syndrome-related cytomegalovirus myelitis. Arch Neurol. 1988 Oct; 45(10):1090-2. Jacobson MA, Mills J, Rush J, O'Donnell JJ, Miller RG, Greco C, Gonzales MF. PMID: 2845899.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    125. Staphylococcus aureus bacteremia and recurrent staphylococcal infection in patients with acquired immunodeficiency syndrome and AIDS-related complex. Am J Med. 1988 Aug; 85(2):172-6. Jacobson MA, Gellermann H, Chambers H. PMID: 3400693.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    126. Prolonged pancytopenia due to combined ganciclovir and zidovudine therapy. J Infect Dis. 1988 Aug; 158(2):489-90. Jacobson MA, de Miranda P, Gordon SM, Blum MR, Volberding P, Mills J. PMID: 3261316.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    127. Randomized prospective trial of ganciclovir maintenance therapy for cytomegalovirus retinitis. J Med Virol. 1988 Jul; 25(3):339-49. Jacobson MA, O'Donnell JJ, Brodie HR, Wofsy C, Mills J. PMID: 2844981.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCellsCTClinical Trials
    128. Treatment of cytomegalovirus retinitis in patients with AIDS. Rev Infect Dis. 1988 Jul-Aug; 10 Suppl 3:S522-31. Mills J, Jacobson MA, O'Donnell JJ, Cederberg D, Holland GN. PMID: 2847289.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    129. Lymphoma in an HIV-positive man after disappearance of a paraprotein. N Engl J Med. 1988 Jun 30; 318(26):1761. Ng VL, Jacobson MA, Khayam-Bashi H, McGrath MS. PMID: 3259675.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    130. Retinal and gastrointestinal disease due to cytomegalovirus in patients with the acquired immune deficiency syndrome: prevalence, natural history, and response to ganciclovir therapy. Q J Med. 1988 Jun; 67(254):473-86. Jacobson MA, O'Donnell JJ, Porteous D, Brodie HR, Feigal D, Mills J. PMID: 2854894.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    131. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. Ann Intern Med. 1988 Apr; 108(4):585-94. Jacobson MA, Mills J. PMID: 2831765.
      View in: PubMed   Mentions: 110     Fields:    Translation:Humans
    132. Cholestasis and disseminated cytomegalovirus disease in patients with the acquired immunodeficiency syndrome. Am J Med. 1988 Feb; 84(2):218-24. Jacobson MA, Cello JP, Sande MA. PMID: 2841850.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    133. Human pharmacokinetics and tolerance of oral ganciclovir. Antimicrob Agents Chemother. 1987 Aug; 31(8):1251-4. Jacobson MA, de Miranda P, Cederberg DM, Burnette T, Cobb E, Brodie HR, Mills J. PMID: 2820301; PMCID: PMC174913.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    134. Development of cytomegalovirus (CMV) retinitis in a patient with AIDS during ganciclovir therapy for CMV colitis. N Engl J Med. 1987 06 18; 316(25):1607-8. O'Donnell JJ, Jacobson MA, Mills J. PMID: 3035374.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    Work in Global Health Equity

    Offer Student Projects

    See more options in the Advanced Search tab

    Mark's Networks
    Concepts (354)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (47)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.